Latest / Stock Movers / Chime, Boston Scientific Falls, Compass Pathways Rises
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: I'm Carol Master along with Tim Stenevik. Let's do that
- 0:19Speaker 2: with our own Bloomberg News Equities Reporter, Avalon Purnell. She's
- 0:22Speaker 2: here in our studio.
- 0:24Speaker 1: All right.
- 0:24Speaker 2: So let's talk post-market, time financial on your radar.
- 0:27Speaker 3: Yes, that's ticker C-H-Y-M. Currently jumping nearly 10% post-market. And
- 0:32Speaker 3: that's after the fintech firm announced that it is buying
- 0:35Speaker 3: Stride Bank for about $ 590 million in cash. Vital Knowledge
- 0:40Speaker 3: actually saying in a note that this deal will help
- 0:42Speaker 3: to merge Chime's IT infrastructure with Stride's bank charter and
- 0:46Speaker 3: banking infrastructure. Worth noting, obviously, Stride has been one of
- 0:50Speaker 3: Chime's bank partners for at least more than seven years,
- 0:54Speaker 3: and they're expecting this deal to be immediately accretive to
- 0:56Speaker 3: their profit, already boosting their third quarter and full-year guidance,
- 1:00Speaker 3: though the deal is not expected to be completed until
- 1:03Speaker 3: the first half of 2027.
- 1:06Speaker 4: So these fintechs haven't necessarily been banks. What they've done
- 1:10Speaker 4: is partnered with banks because from a regulatory perspective, it
- 1:13Speaker 4: was easier to do that. But I guess if you
- 1:15Speaker 4: buy a bank, you can then become a bank.
- 1:17Speaker 2: Says John has for years offered customers checking accounts and
- 1:20Speaker 2: other products and will now be able to do so
- 1:21Speaker 2: in a lower cost fashion by becoming a bank itself.
- 1:26Speaker 1: Yeah.
- 1:27Speaker 4: I bet Paige Smith is all over this story.
- 1:29Speaker 2: Yeah.
- 1:29Speaker 4: She wrote this story. Okay.
- 1:31Speaker 2: There it is. Well done.
- 1:33Speaker 4: Well done.
- 1:35Speaker 2: Look at that. Namaskaran over there.
- 1:40Speaker 4: Excuse me?
- 1:41Speaker 1: Exactly.
- 1:42Speaker 4: All right. From Chime, where are we going next?
- 1:45Speaker 3: Boston Scientific, that's ticker BSX. Not as good news there.
- 1:49Speaker 3: They fell nearly 6% and their worst day since May.
- 1:52Speaker 3: And that's after the medical devices firm said that it's
- 1:54Speaker 3: unlikely that the company will be able to meet its
- 1:56Speaker 3: previously provided guidance for the full year following some cyber
- 1:59Speaker 3: attacks that it experienced at the end of August. Raymond
- 2:02Speaker 3: James also noting that they... are back operational. However, the
- 2:06Speaker 3: fact that they did not actually quantify how much this
- 2:09Speaker 3: is going to weigh, that's really the big problem for
- 2:11Speaker 3: investors ahead.
- 2:12Speaker 1: Cyber attacks.
- 2:13Speaker 2: This is the world we're living in.
- 2:14Speaker 4: This is crazy.
- 2:15Speaker 2: Yeah. But I also think about what it means for
- 2:19Speaker 2: not being able to produce maybe everything they need to,
- 2:21Speaker 2: and certainly for patients and how that impacts them. So
- 2:23Speaker 2: something certainly we're watching. All right, let's go to another post-market, psychedelics.
- 2:28Speaker 1: Yes. Good way to wrap up.
- 2:30Speaker 3: Compass Pathways, that's ticker CMPS, currently gaining about 3.9% post-market.
- 2:36Speaker 3: And that's after Bloomberg reports that the FDA is planning
- 2:38Speaker 3: to tap Mike Davis to remain in charge of CEDAR,
- 2:42Speaker 3: which is a really important branch of the FDA that
- 2:44Speaker 3: oversees the safety, quality, and effectiveness of drugs. And considering
- 2:48Speaker 3: Compass is actually in the lead for potentially getting the
- 2:51Speaker 3: first psychedelic treatment approved, it's definitely something that we're going
- 2:55Speaker 3: to be keeping an eye on and is moving that stock.
- 2:57Speaker 2: We've talked to Kabir Nath a lot.
- 2:58Speaker 4: We have, yeah.
- 2:59Speaker 2: The CEO of Compass.
- 3:01Speaker 4: Yeah, interesting.
- 3:02Speaker 2: Stock's up 103% year-to-date. Okay.
- 3:06Speaker 4: OK, there's this is interesting. Also, the Trump administration cemented
- 3:12Speaker 4: the FDA senior leadership naming officials in charge of regulating drugs,
- 3:15Speaker 4: vaccine and tobacco. One of those people actually has a
- 3:21Speaker 4: background in psychedelics, I believe.
- 3:23Speaker 3: Yes, that's Mike Davis.
- 3:24Speaker 1: Yeah.
- 3:26Speaker 3: There it is.
- 3:27Speaker 2: See, I was listening, which is why I didn't repeat it.
- 3:30Speaker 4: But there's like several of them.
- 3:32Speaker 2: Yeah.
- 3:32Speaker 1: Yes.
- 3:32Speaker 2: No, but, but it speaks to, you're right. You know,
- 3:35Speaker 2: both of you, like, um, what the administration does and
- 3:38Speaker 2: who's appointed and who might have kind of a sympathetic ear, right.
- 3:42Speaker 2: To a certain industry. I missed you, Carol.
- 3:47Speaker 4: So glad you're back.
- 3:50Speaker 2: Are you on psychedelic drugs?
- 3:52Speaker 1: I'm just kidding. I'm just kidding.
- 3:54Speaker 3: He doesn't even drink.
- 3:55Speaker 4: Increasingly.
- 3:56Speaker 2: What?
- 3:57Speaker 1: You are?
- 3:58Speaker 4: No. No, I'm just, you know, increasingly looked at by
- 4:02Speaker 4: some members of the FDA.
- 4:06Speaker 1: Yeah.
- 4:07Speaker 4: As perhaps suitable for treatment for certain things.
- 4:09Speaker 1: Ooh. The Stock Movers Report from Bloomberg Radio. Check back
- 4:16Speaker 1: with us throughout the day for the latest roundup of
- 4:19Speaker 1: companies making news on Wall Street. And for the latest
- 4:22Speaker 1: market-moving headlines, listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:28Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:31Speaker 1: Business app.